Mark Ostrowski has joined GenVault as VP of sales and marketing. Ostrowski spent over a decade with Myriad Genetics Laboratories, finishing his tenure there as director of sales operations. He also was involved in commercialization of pathology and oncology diagnostics at the company Dianon, which later was purchased by LabCorp.
RXi Pharmaceuticals CFO Stephen DiPalma and Athena Diagnostics VP of business development Michael Henry have been named to the board of directors at Neuroptix.
Predictive Biosciences has appointed Martin Madaus to its board of directors. Madaus is president, CEO, and chairman of Millipore and he formerly was VP of development at Roche Molecular Diagnostics and a GM at Boehringer Mannheim.
The National Institutes of Health has tapped Thomas Kelly and Keith Yamamoto to join its Advisory Committee to the Director.
Kelly is a director of the Sloan-Kettering Institute at the Memorial Sloan-Kettering Cancer Center, and a professor at Weill Graduate School of Biomedical Sciences at Cornell University. Kelly spent 30 years at the Johns Hopkins University School of Medicine, where he was director of the Department of Molecular Biology and Genetics and the director of the Institute for Basic Biomedical Sciences.
Yamamoto is a professor of cellular and molecular pharmacology and executive vice dean of the School of Medicine at the University of California, San Francisco, where he also has been vice chair of the department of biochemistry and biophysics and chair of the department of cellular and molecular pharmacology.
Vivian Cheung has been named an investigator by the Howard Hughes Medical Institute. Cheung, who is a pediatric neurologist at the Children’s Hospital of Philadelphia and the University of Pennsylvania School of Medicine, studies the links between gene expression and individual susceptibility to disease and treatment responses.